RxDoctor Payments Data

Emily Miller

Family · New Albany, INNPI 1528396207

Payments from drug & device makers

$8,383in general payments, 2019–2025

Across 379 payments — averaging $22.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$2K
  • Novartis$752
  • Sanofi$510
  • E.r. Squibb & Sons, L.L.C.$441
  • Boehringer Ingelheim$396
  • plus $2K from 18 others

What the payments were for

  • Consulting fees$1,06313%
  • Food & beverage$7,07884%
  • Education$2433%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,383 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$205,455
Medicare patients
1,000
Services billed
4,926

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab12$161,419
Betamethasone Dipropionate123$4,096
Doxycycline Hyclate109$3,299
Clobetasol Propionate44$3,008
Triamcinolone Acetonide264$2,752
Clindamycin Phosphate59$2,206
Ketoconazole86$1,925
ValacyclovirValacyclovir Hcl31$1,206
Fluorouracil14$1,134
Fluocinonide23$1,082
Mupirocin175$1,063
Imiquimod66$990
Gentamicin Sulfate30$877
Doxycycline Monohydrate16$697
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip33$565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$2,399$161,41912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in New Albany

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →